Nitrofurantoin treatment and prophylaxis for recurrent urinary tract infections in women: First-line for a reason. [PDF]
Szlachta-McGinn A, Ackerman AL.
europepmc +1 more source
ABSTRACT Objective There is a lack of studies on seizure outcomes associated with ofatumumab therapy in patients for relapsing anti‐N‐methyl‐D‐aspartate (NMDA) receptor encephalitis. We aimed to evaluate long‐term seizure outcomes of ofatumumab therapy for relapsing anti‐NMDA receptor encephalitis.
Jian Wang, Mengjiao Li, Ping Kong
wiley +1 more source
Bipolar Androgen Therapy as a Potential Mechanistic Bridge to Enhance PARP Inhibitor Efficacy in Prostate Cancer. [PDF]
Jhan JH +4 more
europepmc +1 more source
Diffusion Basis Spectrum Imaging of Tissue Microstructure and Early Treatment in Multiple Sclerosis
ABSTRACT Objective Conventional MRI cannot resolve the coexisting pathological processes within multiple sclerosis tissue. Diffusion Basis Spectrum Imaging decomposes the diffusion signal into fiber, cell, and hindered ratios indexing axonal integrity, cellularity, and extracellular space, respectively.
Apisit Kaewsanit +10 more
wiley +1 more source
Chromosomal instability in cancer: sources, consequences and new therapeutic opportunities. [PDF]
Serpico AF, Grieco D.
europepmc +1 more source
Impact Damage Resistance and Damage Tolerance of Fibre Metal Laminates
A.Vlot, R.S. Fredell
openaire +1 more source
Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley +1 more source
Gas-permeable and stretchable nanoscale anisotropic conductive film for room-temperature, pressure-free interconnections. [PDF]
Katayama S +8 more
europepmc +1 more source
Targeting the DNA Damage Response in Cancer. [PDF]
Qiao Y, Kang B, Zhang J, Zhang R, Li J.
europepmc +1 more source
PARP inhibitors across different malignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies. [PDF]
Ouhajjou A +4 more
europepmc +1 more source

